Semaglutide is an FDA-approved GLP-1 medication that helps regulate appetite, slow digestion, and stabilize blood sugar. It signals your brain that you’re full, making it easier to control portions and reduce cravings. When combined with healthy lifestyle changes, it supports steady, sustainable weight loss—typically through a simple once-weekly injection.

Tirzepatide is a newer medication that targets two key hormones—GLP-1 and GIP—to enhance appetite control and metabolism. This dual action helps reduce hunger, improve blood sugar balance, and support more significant weight loss over time. Like Semaglutide, it’s given as a weekly injection and works best with nutrition and lifestyle guidance.

Ideal candidates are adults who:

Struggle with weight loss despite diet and exercise efforts
Have a BMI of 27 or higher (or 30+ depending on health conditions)
Want a medically supervised, science-based program
Are committed to building sustainable habits alongside treatment

Your provider will review your medical history to determine if GLP-1 therapy is safe and appropriate for you.

These medications may not be suitable for individuals who:

Have a personal or family history of medullary thyroid cancer or MEN type 2
Are pregnant, breastfeeding, or planning pregnancy
Have allergies to any ingredients in the medication
Your provider will screen for these and other medical considerations during your consultation.

Both Semaglutide and Tirzepatide are self-administered as small, once-weekly injections under the skin (abdomen, thigh, or upper arm). You’ll receive clear step-by-step training from your provider to ensure you feel comfortable and confident giving your injections at home.

Results vary by individual, but most clients experience gradual, steady weight loss over several weeks to months. Clinical studies show average total body weight reductions of 10–20% with consistent use, combined with healthy nutrition and lifestyle habits. Many also report more energy, fewer cravings, and improved metabolic health.

Mild side effects such as nausea, bloating, or constipation are common when starting treatment and usually improve as your body adjusts. Taking smaller meals and staying hydrated can help. Serious side effects are rare, but you should contact your provider immediately if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction.

Yes. GLP-1 medications are most effective when paired with balanced nutrition, physical activity, and behavioral support. Your provider will guide you on integrating the medication safely with your current routines or supplements.

Yes. Kimestry Weight Loss offers a fully virtual program for patients across Texas. From consultation to follow-up, everything happens through secure telehealth visits and online communication. Medications are shipped directly to your home, and ongoing support is provided through virtual check-ins.

Your $50 consultation includes a one-on-one telehealth visit with a licensed provider. During the session, your provider reviews your medical history, discusses your goals, and determines whether GLP-1 treatment is a good fit. If eligible, you’ll receive a personalized plan that includes medication guidance, nutrition advice, and follow-up support.

Follow-up appointments are scheduled monthly to track progress, adjust your plan, and ensure your safety and success. Lab work and medication reviews are typically performed every 4–6 months, or as needed.

Kimestry combines medical science with personalized care. Each plan is customized for your body and lifestyle, backed by licensed medical supervision, nutrition guidance, and consistent accountability. It’s not a quick fix—it’s a partnership built around your long-term success.

Important Safety Info for GLP-1s

See Important Safety Information, including Boxed Warning, about:

Wegovy (semaglutide) injection
Zepbound (tirzepatide) injection

Important Safety Information for Wegovy (semaglutide) injection

Warning: Risk of Thyroid C-Cell Tumors

In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. It is not known if Wegovy will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Wegovy if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

What is the FDA-approved use of Wegovy?

Wegovy is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or with overweight plus a weight-related condition.
Wegovy is also used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with known cardiovascular disease and with either obesity or overweight.

Limitations of Use:

Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist

Who should not use Wegovy?

Do not use Wegovy if:

You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to semaglutide (the active ingredient in Wegovy or Ozempic).

How should Wegovy be administered?

You can take Wegovy with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Ro-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.

You should not change your dosing regimen or stop taking Wegovy as prescribed without discussing with your provider first.

What should I tell my Ro-affiliated provider before using Wegovy?

Wegovy has certain drug interactions. It’s important to tell your Ro-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.

Some medications to watch out for include:

Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Wegovy causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
Other medications in the GLP-1 medication class, including Ozempic, Saxenda, Victoza, Byetta, or Bydureon
If you’re using other products for weight loss, including dietary supplements

It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:

Type 1 or type 2 diabetes
Thyroid cancer
Pancreatitis
Kidney disease
Diabetic retinopathy
Depression
Suicidal thoughts or behavior

Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.

If you are pregnant: Wegovy should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Wegovy during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
If you are a female or male of reproductive potential: Discontinue Wegovy at least 2 months before a planned pregnancy since the drug can stay in the bloodstream for a long time.
If you are breastfeeding: Wegovy was found in the milk of lactating rats. Tell your Ro-affiliated provider if you are breastfeeding before you start Wegovy.

Pregnancy registry: There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to semaglutide (the active ingredient in Wegovy and Ozempic) during pregnancy. Pregnant women exposed to semaglutide and healthcare providers are encouraged to contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com.

Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.

What are the most serious side effects that I or a caregiver should monitor for when taking Wegovy?

If you are experiencing a medical emergency, call 911 or seek immediate medical attention.

These serious side effects can occur with Wegovy. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.

Thyroid C-Cell Tumors: In mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused an increase in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether Wegovy causes thyroid C-cell tumors in humans. There were cases of MTC reported in patients who took liraglutide (the active ingredient in Victoza and Saxenda) after the drug was put on the market. Wegovy is contraindicated in patients with a family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Acute Gallbladder Disease: Wegovy may cause gallbladder problems, including gallstones. Some gallbladder problems require surgery. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Low Blood Sugar (hypoglycemia): Wegovy lowers blood glucose. It can cause too low blood sugar in patients who take Wegovy with another glucose control medication, including insulin. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Acute Kidney Injury: In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Severe Gastrointestinal Adverse Reactions: Use of Wegovy has been associated with severe gastrointestinal reactions that are sometimes severe.
Serious Allergic Reactions: Stop using Wegovy right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: If you have type 2 diabetes, tell your provider right away if you experience changes in vision.
Increase in Heart Rate: Tell your provider right away if you have a racing heartbeat while at rest.
Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
Pulmonary Aspiration During General Anesthesia or Deep Sedation: Wegovy causes a delay in gastric emptying. There have been reports of pulmonary aspiration (when food or liquid from the stomach enters the lungs) in people taking GLP-1 medications, including Wegovy, while undergoing surgery requiring sedation, even when instructed to fast before the surgery. If you have a planned major surgery requiring sedation, reach out to your provider for instructions.
Never Share a Pen: Pen-sharing poses a risk of infection.

What are the most common side effects of Wegovy?

Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Headache
Fatigue
Dyspepsia
Dizziness
Abdominal distension
Belching
Hypoglycemia in patients with type 2 diabetes
Flatulence
Gastroenteritis
Gastroesophageal reflux disease

You are encouraged to report negative side effects of prescription products:

Contact Novo Nordisk Inc. at 1-833-934-6891
Contact FDA MedWatch at 1-800-FDA-1088 or visit www.fda.gov/medwatch

This information is not comprehensive. Please see the full Prescribing Information for complete safety information.

Important Safety Information for Zepbound (tirzepatide) injection

Warning: Risk of Thyroid C-Cell Tumors

In rats, Zepbound caused thyroid tumors, including thyroid cancer. It is not known if Zepbound will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

What is the FDA-approved use of Zepbound?

Zepbound is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or with overweight plus a weight-related condition.

Limitations of Use:

Zepbound should not be used in combination with other tirzepatide-containing products or any other GLP-1 receptor agonist.

Who should not use Zepbound?

Do not use Zepbound if:

You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
You have a known allergic reaction to tirzepatide.

How should I take Zepbound?

Zepbound is available as a single-dose pre-filled injector pen or as a single-dose vial with syringe and needle. Both are self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week.

You can take Zepbound with or without food. You should not change your dosing regimen or stop taking Zepbound as prescribed without discussing with your provider first. Your Ro-affiliated provider will guide you on a treatment regimen that may include an increase in dose every four weeks.

What should I tell my Ro-affiliated provider before using Zepbound?

Zepbound has certain drug interactions. It’s important to tell your Ro-affiliated provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.

Some medications to watch out for include:

Medications for diabetes: Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
Other oral medications: Zepbound causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
- Hormonal birth control: If you are using an oral hormonal contraceptive (birth control), Zepbound may decrease its efficacy, especially after the first dose. Switch to a non-oral contraceptive method or use a barrier method of contraception for 4 weeks after starting Zepbound and for 4 weeks after each dose escalation, until you reach the maintenance dose.
Other GLP-1 medications: Including Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, Byetta, or Bydureon. These medications should not be taken with Zepbound.
Other products for weight loss: Including dietary supplements
It’s important to share your entire medical history with your provider. In particular, tell your provider if you have or had a past history of:
- Type 1 or type 2 diabetes
- Thyroid cancer
- Gastrointestinal disease
- Pancreatitis
- Kidney disease
- Diabetic retinopathy
- Depression
- Suicidal thoughts or behavior
Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.
- If you are pregnant: Zepbound should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Zepbound during pregnancy. There is no benefit to weight loss during pregnancy and it may cause harm to the unborn baby.
- If you are a female of reproductive potential: Zepbound may reduce the efficacy of oral hormonal contraceptives. Switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after starting medication and for 4 weeks after each dose escalation until you reach a maintenance dose.
- If you are breastfeeding: It is not known if Zepbound passes into breast milk. Talk to your provider first about the benefits and risks of using Zepbound while breastfeeding.
Pregnancy registry: There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Zepbound during pregnancy. Pregnant patients exposed to Zepbound and healthcare providers are encouraged to contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).

Withholding or providing inaccurate information about your health and medical history in order to obtain treatment may result in harm, including, in some cases, death.

What are the most serious side effects that I or a caregiver should monitor for when taking Zepbound?

If you are experiencing a medical emergency, call 911 or seek immediate medical attention.

These serious side effects are rarer, but can occur with Zepbound. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.

Thyroid C-Cell Tumors: In rats, Zepbound caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors. It is unknown whether Zepbound causes thyroid C-cell tumors in humans. Zepbound is contraindicated in patients with a family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
Severe Gastrointestinal Disease: Zepbound is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe. It hasn’t been studied in patients with severe gastrointestinal disease and isn’t recommended in these patients. The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time.
Acute Kidney Injury: Gastrointestinal side effects of Zepbound like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe. It is important for you to drink plenty of water to help reduce your chance of dehydration.
Acute Gallbladder Disease: Zepbound along with other GLP-1 receptor agonists, and weight loss are associated with an increased chance of acute gallbladder disease. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
Allergic Reactions: Stop using Zepbound right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
Low Blood Sugar (Hypoglycemia): Zepbound lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Rapid improvement of glucose control has been associated with temporary worsening of diabetic retinopathy. Tell your provider right away if you experience changes in vision.
Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
Pulmonary Aspiration During General Anesthesia or Deep Sedation: Zepbound causes a delay in gastric emptying. There have been reports of pulmonary aspiration (when food or liquid from the stomach enters the lungs) in people taking GLP-1 medications, including Zepbound while undergoing surgery requiring sedation, even when instructed to fast before the surgery. If you have a planned major surgery requiring sedation, reach out to your provider for instructions.
Never Share a Pen or Needle: Sharing of pens or needles poses a risk of infection.

What are the most common side effects of Zepbound?

Nausea
Diarrhea
Vomiting
Constipation
Stomach pain
Indigestion
Injection site reactions
Feeling tired
Allergic reactions
Belching
Hair loss
Gastroesophageal reflux disease (heartburn)

You are encouraged to report negative side effects of prescription products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

This information is not comprehensive. Please see the full Prescribing Information for complete safety information.

FREQUENTLY ASKED QUESTIONS

What is Semaglutide and how does it work?

What is Tirzepatide and how is it different?

Who is a good candidate for treatment?

Who may not be a candidate?

How is the medication taken?

What results can I expect?

Are there side effects?

Can these medications be combined with other weight loss methods?

Is the program entirely virtual?

What happens during the first consultation?

How often will I have follow-up visits?

What makes Kimestry Weight Loss different from other programs?

Important safety information for GLP-1 medications